Cargando…

Drug‐Eluting Stent Targeting Sp‐1‐Attenuated Restenosis by Engaging YAP‐Mediated Vascular Smooth Muscle Cell Phenotypic Modulation

BACKGROUND: Activation of the YAP (Yes‐associated protein) pathway has been demonstrated to be related to smooth muscle cells (SMCs) phenotypic modulation and vessel restenosis. The aim of this study was to illustrate the molecular mechanisms that regulate the expression of YAP during the process of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Chen, Zhao, Jie, Zhu, Yuelin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988170/ https://www.ncbi.nlm.nih.gov/pubmed/31880978 http://dx.doi.org/10.1161/JAHA.119.014103

Ejemplares similares

A novel mechanism of inhibiting in-stent restenosis with arsenic trioxide drug-eluting stent: Enhancing contractile phenotype of vascular smooth muscle cells via YAP pathway
por: Zhao, Yinping, et al.
Publicado: (2020)

miRNA-92a inhibits vascular smooth muscle cell phenotypic modulation and may help prevent in-stent restenosis
por: Jiang, Fenfen, et al.
Publicado: (2023)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
por: Dinesch, Violeta, et al.
Publicado: (2017)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Therapeutic Strategy for In-Stent Restenosis Based on the Restenosis Pattern After Drug-Eluting Stent Implantation
por: Kim, Ki-Hun, et al.
Publicado: (2009)

Response to drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
Publicado: (2017)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Effects of a Matrix Metalloproteinase Inhibitor-Eluting Stent on In-Stent Restenosis
por: Song, Jian-bo, et al.
Publicado: (2020)

Drug-eluting stents or balloon angioplasty for drug-eluting stent-associated restenosis: An observational follow-up study of first-time versus repeated restenosis
por: Abdelmegid, Mohamed Aboel-Kassem F., et al.
Publicado: (2017)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Plasma Small Extracellular Vesicle-Carried miRNA-501-5p Promotes Vascular Smooth Muscle Cell Phenotypic Modulation-Mediated In-Stent Restenosis
por: Gao, Xiao-Fei, et al.
Publicado: (2021)

Predictors of diffuse-type in-stent restenosis following drug-eluting stent implantation
por: PARK, CHANG-BUM, et al.
Publicado: (2013)

Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence
por: Condello, Francesco, et al.
Publicado: (2023)

Long Non-Coding RNAs Might Regulate Phenotypic Switch of Vascular Smooth Muscle Cells Acting as ceRNA: Implications for In-Stent Restenosis
por: Arencibia, Alberto, et al.
Publicado: (2022)

In-Stent Restenosis due to Stent Recoil After Third-Generation Drug-Eluting Stent Implantation
por: Kato, Yuta, et al.
Publicado: (2017)

The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty
por: Oh, Pyung Chun, et al.
Publicado: (2016)

Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents
por: Liu, Yen-Wen, et al.
Publicado: (2021)

Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis
por: Yin, Rui-Xing, et al.
Publicado: (2014)

Intravascular Ultrasound-Guided Treatment for In-stent Restenosis Associated with Stent Fracture in Overlapped Drug-eluting Stents
por: Kim, Min Chul, et al.
Publicado: (2019)

Impact of Exercise-based Cardiac Rehabilitation on In-stent Restenosis with Different Generations of Drug Eluting Stent
por: Kim, Chul, et al.
Publicado: (2012)

Local drug-delivery balloon for proliferative occlusive in-stent restenosis after drug-eluting stent
por: Rigatelli, Gianluca, et al.
Publicado: (2011)

Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents
por: Yin, Jiasheng, et al.
Publicado: (2017)

In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario
por: Paramasivam, Ganesh, et al.
Publicado: (2019)

Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation
por: Luo, Yinhua, et al.
Publicado: (2022)

Ending Restenosis: Inhibition of Vascular Smooth Muscle Cell Proliferation by cAMP
por: Smith, Sarah A., et al.
Publicado: (2019)

Effect of Atorvastatin-Eluting Stents in a Rabbit Iliac Artery Restenosis Model
por: Lim, Kyung Seob, et al.
Publicado: (2013)

Early Restenosis of Sirolimus-eluting Stent: An Unusual Case of a Hyperthyroid Patient
por: Shabbir, Syeda Javeria, et al.
Publicado: (2019)

Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis
por: Cui, Kong-Yong, et al.
Publicado: (2018)

Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent restenosis: an updated meta-analysis of randomized studies
por: Gao, Lei, et al.
Publicado: (2019)

Reduction of In-Stent Restenosis and Inflammation with One Stent: New Concept of Sirolimus and Ascorbic Acid-Eluting Coronary Stent
por: Ryu, JiWung, et al.
Publicado: (2021)

Value of S100A12 in predicting in-stent restenosis in patients with coronary drug-eluting stent implantation
por: Liang, Hengyi, et al.
Publicado: (2020)

The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era
por: Zheng, Chengbin, et al.
Publicado: (2019)

In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes
por: Paramasivam, Ganesh, et al.
Publicado: (2020)

Hif-1α/Slit2 Mediates Vascular Smooth Muscle Cell Phenotypic Changes in Restenosis of Bypass Grafts
por: Li, Sen, et al.
Publicado: (2023)

Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2017)

The association between epicardial fat thickness in echocardiography and coronary restenosis in drug eluting stents
por: Nikaeen, Fariborz, et al.
Publicado: (2011)

Association of Triglyceride Deposit Cardiomyovasculopathy With Drug-Eluting Stent Restenosis Among Patients With Diabetes
por: Nakano, Yusuke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_280p9ff5r8mlnsiin7hggun2gb